RAPID TRACKED UK DELIVERY ONLY £1.95 & FREE FOR ORDERS OVER £75USE CODE BLACKFRIDAY FOR EXTRA 15% OFF!Order before 4pm Monday–Friday for same-day dispatch with Royal Mail Tracked 24THIRD-PARTY LAB-TESTED COA's AVAILABLELAB-CERTIFIED QR CODES FOR PROOF OF AUTHENTICITYUK BASED & ISO CERTIFIED MANUFACTURINGDISCREET PLAIN PACKAGING WITH NO EXTERNAL PRODUCT IDENTIFICATIONRAPID TRACKED UK DELIVERY ONLY £1.95 & FREE FOR ORDERS OVER £75USE CODE BLACKFRIDAY FOR EXTRA 15% OFF!Order before 4pm Monday–Friday for same-day dispatch with Royal Mail Tracked 24THIRD-PARTY LAB-TESTED COA's AVAILABLELAB-CERTIFIED QR CODES FOR PROOF OF AUTHENTICITYUK BASED & ISO CERTIFIED MANUFACTURINGDISCREET PLAIN PACKAGING WITH NO EXTERNAL PRODUCT IDENTIFICATION

RAD-140 Side Effects: What Human Research Reveals

RAD-140 (Testolone) is a selective androgen receptor modulator (SARM) that has attracted scientific interest for its distinctive receptor activity and potential applications in androgen-responsive tissues.

Alongside promising preclinical findings, researchers have investigated its tolerability during early human clinical development.

The available evidence provides useful insight into RAD-140’s biological activity and safety profile, although findings must be interpreted within the specific populations studied.

What Did the First Human RAD-140 Trial Reveal?

A Phase I investigation published in Clinical Breast Cancer in 2022 examined RAD-140 in 22 postmenopausal women with advanced breast cancer.

The participants had undergone extensive previous cancer treatment, making this a specialised clinical population rather than a study of healthy adults.

Researchers assessed tolerability, pharmacokinetics and evidence of androgen receptor activity.

The investigation demonstrated measurable androgen receptor engagement, alongside preliminary anti-tumour activity in a small number of participants.

The researchers concluded that RAD-140 had an acceptable safety profile within the investigated oncology setting, supporting further clinical research.

Read the published RAD-140 Phase I study.

What Side Effects Were Observed?

The most frequently reported treatment-emergent findings included:

  • Elevated AST: 59.1% of participants.

  • Elevated ALT: 45.5% of participants.

  • Elevated bilirubin: 27.3% of participants.

  • Vomiting, dehydration and decreased appetite: 27.3% each.

AST and ALT are enzymes commonly measured when investigating liver function, while bilirubin provides additional information about liver and bile-processing activity.

Importantly, these figures represent events recorded during treatment, not proof that every event was caused exclusively by RAD-140.

Seven of the 22 participants experienced severe treatment-related adverse events, although no Grade 4 treatment-related events were recorded.

Because the investigation involved patients with advanced cancer receiving experimental oncology treatment, these percentages cannot be used to predict side-effect rates in healthy individuals.

What About Liver Health?

Liver-related findings represent one of the most important areas of ongoing RAD-140 safety research.

The Phase I investigation recorded frequent liver-test abnormalities, including some severe elevations.

Published case reports have also described liver injury following the use of products containing RAD-140.

However, individual case reports can be complicated by uncertainties involving product composition, other substances and underlying medical factors.

The evidence therefore supports continued investigation into liver-related effects rather than assuming RAD-140 is either harmless or directly comparable with conventional anabolic steroids.

Read a published RAD-140 liver-injury case report.

Does RAD-140 Affect Natural Hormone Levels?

RAD-140 activates androgen receptors but does not convert directly into oestrogen or DHT through the conventional testosterone pathways.

Nevertheless, androgen receptor activity can potentially influence hormonal feedback mechanisms.

The available human RAD-140 trials have not adequately established the frequency or extent of testosterone suppression in healthy men.

For more information about its distinctive molecular properties, see our RAD-140 and Hormone Conversion Research.

Why Does RAD-140 Continue to Attract Research Interest?

RAD-140 was developed to investigate selective androgen receptor activity and its potential effects across different tissues.

Preclinical studies have demonstrated interesting biological responses, while early clinical development has confirmed measurable receptor engagement in humans.

These findings provide a scientific foundation for further investigation, particularly into tissue selectivity and the relationship between biological activity and tolerability.

For broader context, visit our Complete SARMs Research Guide.

Final Thoughts

RAD-140 has demonstrated meaningful androgen receptor activity in experimental research, with early human investigations providing important clinical observations.

Although liver-test abnormalities and other adverse events were recorded, the principal Phase I trial involved a small, heavily pretreated oncology population, making broader comparisons unreliable.

The most scientifically useful conclusion is that RAD-140 has demonstrated biological activity in humans, while its safety profile outside specialised clinical settings remains insufficiently established.

Further controlled investigations are needed to clarify its longer-term effects and tolerability.

Research Use Only: RAD-140 is an investigational compound not approved for human consumption as a sports supplement. Its long-term safety and effectiveness for bodybuilding or performance enhancement have not been established.

Leave a Reply

Your email address will not be published. Required fields are marked *

Are you human? Please solve:Captcha